Find Clinical Trials | Cedars-Sinai

401 results found

Brain and Nervous System

NRG, NRG-BN013, Ph 3, Randomized, Brain Mets, SRS vs fSRS

Primary Objective: To determine if the time to local failure is improved with FSRS compared to SRS in patients with intact (i.e., unresected) brain metastases. Secondary Objectives: I. To compare time to intracranial progression-free survival between FSRS ...

Ovary

Regeneron Pharmaceuticals, Inc.R4018-ONC-2445,Ph2,Open label,rand,Ovarian CA, Ubamatamab +/- SOC Ob

Primary - Efficacy To assess the Objective Response Rate (ORR) of ubamatamab alone or in combination with bevacizumab, cemiplimab + fianlimab, or PLD (separately by study arm). Secondary: Efficacy: To assess preliminary efficacy of Ubamatamab combinations as measured by changes ...

Colon

Endevica Bio, TCMCB07-01, Ph2, Open-label, dbl-blind, Colon Cancer, TCMCB07 vs placebo

Primary Objective: To evaluate the safety of B07. Secondary Objectives: To evaluate the effect of B07 by dose level on weight, BMI, and body composition relative to placebo, over 28 days in newly diagnosed metastatic colorectal cancer patients. To ...

Unknown Sites

Verastem Oncology, VS-7375-101, Ph 1/2, Open, KRAS G12D-Mutant solid tumors, VS-7375

Primary Objective: Part A: VS-7375 Single Agent Dose Escalation To characterize the safety, tolerability, and AE profile of escalating doses of VS-7375 as 2L+ monotherapy administered on a daily oral schedule in participants with any KRAS ...

Unknown Sites

Exelixis, Inc., XL092-311, Ph 2/3, randomized, Zanzalinitinib vs Everolimus, Neuroendocrine tumors

Primary Objective: To evaluate progression-free survival (PFS) by blinded independent central review (BICR) of zanzalintinib versus everolimus Secondary Objectives: To evaluate objective response rate (ORR) by BICR of zanzalintinib versus everolimus To evaluate overall survival (OS) of ...